The therapeutic potential of HDAC and HAT inhibitors in ischemic stroke has gained increasing attention due to their roles in epigenetic regulation of neuroinflammation, oxidative stress, and neuronal survival. This evidence concerns the gene TMPRSS11D and ischemic stroke.